Skip to main content

Table 2 Association between TERT promoter mutations and clinicopathologic features in 222 patients with well-differentiated thyroid carcinoma

From: Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation

  TERT promoter mutations  
Absent (n = 210) Present (n = 12) p-value
Age (mean years) 45.5 ± 13.3 55.0 ± 11.8 0.017
Gender    
 Female 164 (94.8 %) 9 (5.2 %) 0.801
 Male 46 (93.9 %) 3 (6.1 %)
Tumor size (mean mm) 14.8 ± 12.5 31.9 ± 22.9 0.043
Histologic types    
 Aggressive varianta) 18 (75.0 %) 6 (25.0 %) <0.001
 Less-aggressive variant 192 (97.0 %) 6 (3.0 %)
Pathologic T stage    
 pT 1–2 97 (99.0 %) 1 (1.0 %) 0.014
 pT 3–4 113 (91.1 %) 11 (8.9 %)
Extrathyroidal extension    
 Absent 105 (98.1 %) 2 (1.9 %) 0.035
 Present 105 (91.3 %) 10 (8.7 %)
Pathologic N stage    
 pN0 105 (99.1 %) 1 (0.9 %) 0.011
 pN1 105 (91.3 %) 10 (8.7 %)
Lateral lymph node metastasis    
 Absent 166 (98.8 %) 2 (1.2 %) <0.001
 Present 43 (82.7 %) 9 (17.3 %)
Distant metastasis    
 Absent 192 (100 %) 0 <0.001
 Present 18 (60.0 %) 12 (40 %)
AJCC stage    
 I-II 120 (100 %) 0 <0.001
 III-IV 90 (88.2 %) 12 (11.8 %)
BRAF V600E mutation    
 Absent 62 (95.4 %) 3 (4.6 %) 0.738
 Present 148 (94.3 %) 9 (5.7 %)
  1. a)Aggressive variant includes 21 tall cell, 1 columnar cell, and 1 diffuse sclerosing variant of papillary carcinoma and 1 widely invasive follicular carcinoma